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11 November 2015WHAT IS ALREADY KNOWN ABOUT
AIMS
In vivo platelet function is a product of intrinsic platelet reactivity,
modiﬁable by dual antiplatelet therapy (DAPT), and the extrinsic
inhibitory endothelial mediators, nitric oxide (NO) and prostacyclin
(PGI2), that are powerfully potentiated by P2Y12 receptor blockade. This
implies that for individual patients endothelial mediator production is
an important determinant of DAPT effectiveness. Here, we have
investigated this idea using platelets taken from healthy volunteers
treated with anti-platelet drugs.and prostacyclin (PGI2).
• NO and PGI2 also independently amplify METHODS
Three groups of male volunteers (n = 8) received either prasugrel
(10 mg), aspirin (75 mg) or DAPT (prasugrel + aspirin) once daily for
7 days. Platelet reactivity in the presence of diethylammonium (Z)-1-(N,
N-diethylamino)diazen-1-ium-1,2-diolate (DEA/NONOate) and PGI2
was studied before and following treatment.• Three way synergy between PGI2, NO and
RESULTS
Ex vivo, PGI2 and/or DEA/NONOate had little inhibitory effect on TRAP-
6-induced platelet reactivity in control conditions. However, in the
presence of DAPT, combination of DEA/NONOate + PGI2 reduced
platelet aggregation (74 ± 3% to 19 ± 6%, P < 0.05). In vitro studies
showed even partial (25%) P2Y12 receptor blockade produced a
signiﬁcant (67 ± 2% to 39 ± 10%, P < 0.05) inhibition when DEA/
NONOate + PGI2 was present.and associations to platelet cyclic
nucleotides in vivo could improve CONCLUSIONS
We have demonstrated that PGI2 and NO synergize with P2Y12 receptor
antagonists to produce powerful platelet inhibition. Furthermore, even
with submaximal P2Y12 blockade the presence of PGI2 and NO greatly
enhances platelet inhibition. Our ﬁndings highlight the importance of
endothelial mediator in vivo modulation of P2Y12 inhibition and
introduces the concept of reﬁning ex vivo platelet function testing by
incorporating an assessment of endothelial function to predict
thrombotic outcomes better and adjust therapy to prevent adverse
outcomes in individual patients.acol / 81:4 / 621–633 / 621
istribution and reproduction in any medium,
M. V. Chan et al.Introduction To test this hypothesis we added NO and PGI2 to standard
ex vivo tests of platelet function in blood taken fromCompromise in the integrity of the vascular endothelium
precipitates rapid platelet activation as platelets become
exposed to sub-endothelial collagen and tissue factor.
This activation is driven by a cascade of complex intra-
cellular signalling pathways leading to the production
of secondary platelet agonists, notably thromboxane
(TX) A2 and ADP [1, 2]. Dual anti-platelet therapy (DAPT)
is recommended for the secondary prevention of
atherothrombotic events in patients with acute coronary
syndromes or following percutaneous coronary inter-
vention [3, 4] and targets these two pathways with a
P2Y12 receptor antagonist, such as clopidogrel, prasugrel
or ticagrelor, and aspirin. The P2Y12 receptor blockers
inhibit platelet aggregation by blocking the amplifying
effects of ADP acting on platelet P2Y12 receptors [5],
while aspirin targets the TXA2-dependent pathway by
inhibiting the cyclooxygenase (COX) enzyme within
platelets [6]. Whilst DAPT is associated with an improve-
ment in patient outcomes, thrombotic events do still
occur. An often explored hypothesis is that the risk of
experiencing a thrombotic event is associated with the
level of platelet blockade, i.e. those individuals with less
effective blockade provided by aspirin and, particularly
P2Y12 receptor blockers, are more at risk of thrombotic
events. However, studies have failed to show any bene-
ﬁts from ex vivo monitoring of platelet function and sub-
sequent tailoring of treatment in patients receiving dual
anti-platelet therapy [7–10]. This failure is possibly be-
cause the ex vivo platelet tests used in these trials do
not consider the environment in which platelets reside
in vivo. Namely that within the circulation endothe-
lium-derived autacoids, nitric oxide (NO) and prostacy-
clin (PGI2), reduce platelet reactivity and prevent
inappropriate platelet activation [11, 12]. Indeed, within
the circulation each platelet is balanced by approxi-
mately 50 endothelial cells (e.g. 1.25 trillion platelets vs.
60 trillion endothelial cells in a 70 kg man) [13].
NO diffuses freely into platelets activating guanylyl
cyclase (GC) to increase intracellular cGMP levels [14],
while PGI2 binds to IP receptors activating adenylyl
cyclase (AC) to increase intracellular cAMP levels [15].
Elevations in the intracellular levels of individual cyclic
nucleotides promotes a generalized inhibition of platelet
function [16] and the two pathways synergize to produce
particularly strong inhibition [12]. NO and PGI2 also
individually synergize with P2Y12 inhibition producing
robust anti-aggregatory platelet effects [17, 18].
Taking account of the above observations we hypoth-
esized that within the circulation the levels of endothe-
lium-derived mediators are an important determinant
of the efﬁcacy of DAPT. Therefore, for individual patients
in vitro measures of platelet reactivity do not accurately
predict the in vivo effectiveness of DAPT due to the con-
founding of differences in endothelial mediator production.622 / 81:4 / Br J Clin Pharmacolhealthy volunteers receiving anti-platelet therapies.Methods
Study participants
Twenty-four healthy, non-smoking male volunteers
(aged 18–40 years) were recruited and participated in
the study. Health status was determined though medi-
cal history and physical examination, including blood
pressure, pulse rate, blood chemistry and urinalysis.
Volunteers with normal clinical proﬁles were included
in the study. The study was approved by St Thomas’s
Hospital Research Ethics Committee (Ref. 07/Q0702/24)
and all volunteers gave written consent before entering
the study.
Study protocol
Healthy volunteers abstained from aspirin, non-steroidal
anti-inﬂammatory drugs (NSAIDs) and any other anti-
platelet therapy for 14 days before commencing the
study. The volunteers were divided into groups of eight.
The ﬁrst group received aspirin (75 mg; Nu-Seals Cardio
75, Alliance Pharmaceuticals Ltd, Chippenham, UK), the
second prasugrel (10 mg; Efﬁent®, Eli Lilly, RA Houten,
The Netherlands) and the third both aspirin (75 mg)
and prasugrel (10 mg) to represent DAPT for 7 days.
Adherence was assessed by interview. Blood samples
were collected before and after drug treatment.
Blood collection
Blood for platelet aggregation was collected by
venepuncture into tri-sodium citrate (0.32% ﬁnal; Sigma,
Poole, Dorset, UK). Platelet-rich plasma (PRP) was ob-
tained by centrifugation at 175 × g for 15 min at 25 °C.
Platelet-poor plasma (PPP) was obtained by centrifuga-
tion of PRP at 15 000 × g for 2 min. All experiments were
completed within 2 h of blood collection.
Incubation with platelet function inhibitors
For in vitro incubation experiments, PRP was treated with
either vehicle (0.5% DMSO) or the P2Y12 receptor blocker
prasugrel active metabolite (PAM; a kind gift of
AstraZeneca) at 1.5 μM, 3 μM or 6 μM, to represent 25%,
50% or 100% of the concentration needed for complete
P2Y12 receptor blockade, respectively, in the absence or
presence of aspirin (acetylsalicylic acid, ASA, 30 μM) for
30 min at 37 °C.
Light transmission aggregometry (LTA)
Baseline aggregation of PRP to arachidonic acid (AA, ﬁnal
concentration, 1 mM, Sigma), adenosine diphosphate
(ADP, 5–20 μM, Labmedics, Salford, Manchester, UK),
Horm collagen (0.4 and 10 μg ml1, Nycomed, Linz,
NO and PGI2 synergize with P2Y12 receptor blockadeAustria) and U46619 (10 μM, Cayman Chemical Company,
Ann Arbor, MI, USA) was measured in a Bio/Data PAP-8E
turbidimetric aggregometer (1200 rev min1, 37 °C;
Alpha Laboratories, Eastleigh, UK) before and following
treatment. Aggregations to TRAP-6 amide speciﬁc for
PAR1 (TRAP-6, 25 μM, SFLLRN, Bachem, Bubendorf,
Switzerland) or Horm collagen (4 μg ml1) after
pre-incubation (1 min, 37 °C) with the NO donor
diethylammonium (Z)-1-(N,N- diethylamino)diazen-1-
ium-1,2-diolate (DEA/NONOate, 100 nM, Sigma) and/or
prostacyclin (PGI2, 1 nM, R&D systems, Abingdon, UK) or
vehicle (NaOH, 10 mM, Sigma) were also recorded. Using
an NO measuring system (iNO600, Harvard apparatus) we
showed 83 nM NO release at 2 min and 154 nM at 4 min
when 100 nM DEA/NONOate was incubated at pH 7.4.
Isobolographic analysis
Inhibitory concentration curves for PGI2 (1–8 nM) or
DEA/NONOate (10 nM – 1 μM) against aggregation
induced by TRAP-6 (25 μM) or collagen (30 μg ml1) in
the presence of vehicle or PAM (6 μM) were constructed
with data ﬁtted to a logistic equation using least
squares method (Prism 6.0e, GraphPad Software, La
Jolla, CA, USA). Derived data were used to generate
isobolograms [18, 19].
ADP + ATP secretion
PRP was pre-incubated for 1 min with DEA/NONOate,
PGI2 or vehicle in an optical lumi-aggregometer (560
CA, Chronolog, Havertown, PA, USA). ADP + ATP
secretion was evaluated by luminescence in the presence
of Chrono-Lume reagent (0.2 μM luciferin/luciferase,
Chronolog) after stimulation with TRAP-6 (25 μM) or
collagen (4 μg ml1).
P-selectin expression and GPIIb/IIIa activation
PRP, pre-incubated with PAM or vehicle, as described
earlier, was incubated with PGI2, DEA/NONOate or
vehicle and then activated with TRAP-6 (25 μM) with
gentle mixing at 37 °C. After 2 min, the reaction was
stopped by dilution with a 10-fold excess of cold saline.
Platelets were immediately stained with anti-CD61-
allophycocyanin (CD61-APC, eBioscience, Hatﬁeld, UK),
PAC-1-FITC (BD Bioscience, Oxford, UK), and anti–
P-selectin-PE (eBioscience) for 15 min at 4 °C and then
ﬁxed in 2% (v/v) formalin (Sigma). PAC-1-FITC and
anti-P-selectin-PE immunoreactivity was measured by
ﬂow cytometry using a FACSCalibur instrument (Becton
Dickinson, Oxford, UK). Representative histograms are
shown in Supplementary Figure 5A–D.
VASP phosphorylation
PAM or vehicle-treated PRP was stimulated with collagen
(4 μg ml1) or TRAP-6 (25 μM) in the presence of PGI2,
DEA/NONOate or vehicle. After 4 min, the reaction was
stopped with methanol-free formaldehyde (2% ﬁnal,Fisher Scientiﬁc). Platelets were permeabilized (0.2% Tri-
ton X-100, Sigma) and incubated with anti-vasodilator
stimulated phosphoprotein (VASP)-P(Ser239) primary
antibody (Enzo Life-sciences, Exeter, UK), Alexa647-
conjugated secondary antibody (Invitrogen, Paisley, UK)
and FITC-conjugated anti-CD42b (eBioscience, Hatﬁeld,
UK), for 30 min each, in turn, before the platelet pellet
was resuspended in 0.9% saline. VASP-P(Ser239) immuno-
reactivity was measured by ﬂow cytometry, using a
FACS-Calibur instrument (Becton Dickinson). Representa-
tive histograms are shown in Supplementary Figure 5E,F.
cAMP and cGMP measurements
PAM or vehicle-treated PRP was stimulated with collagen
(4 μg ml1) or TRAP-6 (25 μM) in the presence of PGI2,
DEA/NONOate or vehicle. After 4 min, platelets were
lyzed with Triton-X-100 (0.625%) and treated with iso-
butylmethylxanthine (IBMX, 500 μM) and potassium
ﬂuoride (0.5 M). cAMP and cGMP concentrations were
determined by homogenous time-resolved ﬂuorescence-
based competitive immunoassays (Cisbio Bioassays,
Codolet, France).
Statistics and data analysis
Data were analyzed using Prism 6.0e. Summary data
(IC50, EC50) were obtained by ﬁtting of data to a logistic
equation and tested by Student’s t-test (two groups) or
one way ANOVA (>two groups). Flow data were analyzed
using FlowJo v8.7 (Treestar, Ashland, USA) where the ‘sin-
gle platelet’ population was gated based on forward
scatter and CD61-APC immunoreactivity (FL-4 mean
ﬂuorescence intensity). Statistical signiﬁcance was
determined by two way ANOVA with Dunnett’s post hoc
test unless otherwise stated and data sets considered
different if P < 0.05.
P2Y12 nomenclature conforms to the BJCP guidelines.Results
Light transmission aggregation responses
following in vivo mono and dual anti-platelet
therapy
In individuals taking aspirin, standard LTA responses to
AA (1 mM) were strongly inhibited, as were responses
to collagen. Responses to ADP (5 μM) were also signiﬁ-
cantly reduced, although to a lesser degree, while those
to U46619 (10 μM) were unaffected (Supplementary
Figure 1A). In individuals taking prasugrel, aggregatory
responses to AA, collagen, ADP and U46619 were all
signiﬁcantly reduced (Supplementary Figure 1B). Aggre-
gations induced by AA, collagen and ADP were
abolished in individuals taking DAPT (Supplementary
Figure 1C) while responses to U46619 were strongly
reduced.Br J Clin Pharmacol / 81:4 / 623
M. V. Chan et al.Platelet aggregation, ATP secretion, P-selectin
expression and GPIIb/IIIa activation in the
presence of PGI2 and DEA/NONOate together
with DAPT
In blood from individuals before DAPT, PGI2 (1 nM),
DEA/NONOate (100 nM) or DEA/NONOate + PGI2 had
little effect upon platelet aggregation. Following DAPT, col-
lagen (4 μg ml1)-induced aggregation was signiﬁcantly
reduced from 73 ± 2% to 31 ± 2% (P < 0.05, Figure 1A
and Supplementary Figure 2A), as seen previously with aFigure 1
Interactions of NO and PGI2 with DAPT: platelet aggregation and ATP release. B
lagen (4 μg ml1), and (B) TRAP-6 amide (25 μM), and (C) ATP release in respon
after 7 days DAPT (aspirin, 75 mg, plus prasugrel, 10 mg). Aggregometry conduc
or NO + PGI2. Data are presented as ﬁnal aggregation (%, mean ± SEM) or ATP
ATP release with red and minimum aggregation or ATP release with green. n = 8
NaOH DAPT-treated ‡ P < 0.05 vs. PGI2 DAPT-treated. ( ) Pre-treatment , ( )
624 / 81:4 / Br J Clin Pharmacollower concentration of collagen (0.4 μg ml1, Supplemen-
tary Figure 1A). TRAP-6 (25 μM)-induced aggregation was,
however, unaffected by DAPT unless DEA/NONOate + PGI2
was present, when it was substantially reduced (67 ± 3%
to 19 ± 6%, P < 0.05, Figure 1B). In parallel experiments,
we used lumi-aggregometry to quantify ADP + ATP release
as a measure of dense granule secretion (Supplementary
Figure 2B). These studies indicated that TRAP-6 induced
dense granule secretion was unaffected in individuals
receiving DAPT administration but was reduced with thear graphs and heatmaps of platelet aggregation in response to (A) col-
se to TRAP-6 amide (25 μM). Aggregometry was conducted before and
ted in the presence of vehicle (NaOH, 10 mM), NO (100 nM), PGI2 (1 nM),
release (nM, mean ± SEM). Heatmaps indicate maximum aggregation or
for all. Signiﬁcance is shown as * P< 0.05 vs. non-treated, † P< 0.05 vs.
DAPT
NO and PGI2 synergize with P2Y12 receptor blockadefurther addition of DEA/NONOate + PGI2 (6.3 ± 1.9 to
3.7 ± 1.3 nM, P < 0.05, Figure 1C). Likewise, this was seen
in collagen-induced ATP release after aspirin or prasugrel
alone (Supplementary Figure 4).
Similar effects were found in individuals receiving
prasugrel, in whom aggregation in response to TRAP-6
was signiﬁcantly reduced (63 ± 3% to 7 ± 3%, P < 0.05,
Supplementary Figure 3D) by the addition of DEA/
NONOate + PGI2. Treatment with aspirin alone signiﬁ-
cantly reduced collagen-induced aggregation in the
presence of both DEA/NONOate (58 ± 9% to 36 ± 8%,
P < 0.05, Supplementary Figure 3A) and PGI2 (66 ± 5% to
35 ± 7, P < 0.05, Supplementary Figure 3A). Following treat-
ment with aspirin, TRAP-6-induced aggregation was unaf-
fected by DEA/NONOate or PGI2, but was reduced by DEA/
NONOate + PGI2 (58 ± 8% to 28 ± 9%, P< 0.05, Supplemen-
tary Figure 3B). To aid in visualization of results these data are
also expressed as heatmaps (Supplementary Figure 3E, F).
In individuals receiving DAPT, TRAP-6-induced
P-selectin expression (geometric mean ﬂuorescence
index, MFI, 29.0 ± 7.5 units to 2.4 ± 0.6 units, P < 0.05,
Supplementary Figure 6A) and PAC-1 binding
(12.4 ± 3.4 units to 1.3 ± 0.5 units, P < 0.05, Supplemen-
tary Figure 6B) were signiﬁcantly reduced. This pattern
was similar with regard to P-selectin expression
(25.0 ± 6.1 units to 8.8 ± 3.4 units, P < 0.05) and PAC-1
binding (19.2 ± 3.7 units to 1.6 ± 0.3 units, P < 0.05) in
individuals receiving prasugrel only. Treatment with
aspirin alone had no effect on either P-selectin or PAC-1
binding.Effects of PGI2 and DEA/NONOate on platelet
aggregation and ATP release in the presence of
submaximal P2Y12 antagonism is sufﬁcient to
produce platelet inhibition
PRP was taken from healthy volunteers and pre-treated
in vitro with prasugrel-active metabolite (PAM, 1.5 μM,
3 μM and 6 μM) to represent 25%, 50% and 100% of the
concentration of PAM required for total P2Y12 receptor
inhibition in the absence (Table 1A) and presence (Table 1B)
of aspirin. Aggregation in response to ADP (20 μM) was in-
creasingly inhibited with increasing levels of PAM: control,
73 ± 5%; aspirin, 51 ± 7%; aspirin + PAM-25%, 33 ± 11%; as-
pirin + PAM-50%, 23 ± 8%; aspirin + PAM-100%, 7 ± 1%
(P < 0.05).
Maximum platelet aggregation to collagen in the
presence of PAM-100% was reduced by the addition of
DEA/NONOate (74 ± 4% to 23 ± 9%, P < 0.05), PGI2
(74 ± 4% to 22 ± 6%, P < 0.05) and DEA/NONOate + PGI2
(50 ± 10% to 4 ± 1%, P < 0.05). Similarly, TRAP-induced
aggregation was reduced in the presence of DEA/
NONOate (70 ± 2% to 36 ± 6%, P < 0.05), PGI2 (67 ± 2%
to 35 ± 3%, P < 0.05) and DEA/NONOate + PGI2
(63 ± 3% to 4 ± 2%, P < 0.05). Indeed, even with submax-
imal PAM-50% and PAM-25% P2Y12 receptor inhibition,signiﬁcant inhibition of platelet aggregation was found
following addition of DEA/NONOate and PGI2.
Although aspirin alone inhibited collagen-induced
platelet aggregation, TRAP-6-induced aggregation was
only signiﬁcantly inhibited with the further addition of
DEA/NONOate + PGI2 to aspirin + PAM-100% (58 ± 5 to
15 ± 8%, P < 0.05), aspirin + PAM-50% (67 ± 6% to
33 ± 15%, P < 0.05) and even aspirin + PAM-25%
(70 ± 4% to 36 ± 13%, P < 0.05, Table 2B).
Collagen (4 μg ml1)-induced ATP release was signif-
icantly inhibited by DEA/NONOate + PGI2 in the presence
of PAM-100% (8.2 ± 2.1 nM to 2.3 ± 0.5 nM), PAM-50%
(10.1 ± 2.9 nM to 4.0 ± 1.8 nM, P < 0.05) and PAM-25%
(11.0 ± 3.0 nM to 4.1 ± 1.7 nM, P < 0.05; Table 2A), but
not by DEA/NONOate or PGI2 alone. Similarly, in the pres-
ence of aspirin (Table 2B), collagen-induced ATP release
was signiﬁcantly reduced by DEA/NONOate + PGI2 with
submaximal levels of P2Y12 blockade (aspirin + PAM-
0%, 8.0 ± 0.5 nM; aspirin + PAM-25%, 1.9 ± 0.3 nM,
P < 0.05; aspirin + PAM-50%, 2.1 ± 0.3, P < 0.05; aspi-
rin + PAM-100%, 1.8 ± 0.2 nM, P < 0.05).Synergy between PGI2, DEA/NONOate and
P2Y12 blockade
Isobolographic analyses indicated strong synergistic in-
hibition between DEA/NONOate and PGI2 against plate-
let aggregation induced by collagen (30 μg ml1,
Figure 2A) or TRAP-6 amide (25 μM, Figure 2B), with
isoboles curving strongly towards the axes. P2Y12 block-
ade caused a further powerful (5-fold and 10-fold, re-
spectively) enhancement in the synergy between DEA/
NONOate and PGI2 for the inhibition of aggregations in-
duced by collagen (Figure 2B) and TRAP-6 (Figure 2D).Involvement of cAMP and cGMP in the
synergistic effects of P2Y12 blockade, PGI2 and
DEA/NONOate
We found no signiﬁcant change in cGMP levels in the
platelets in response to DEA/NONOate and/or PGI2 after
incubation with aspirin, PAM or aspirin + PAM after plate-
let aggregation stimulated by collagen (Figure 3A) or
TRAP-6 (Figure 3B).
In collagen-stimulated platelets, cAMP levels
(0.8 ± 0.1 nM) were not altered by DEA/NONOate, but
were signiﬁcantly increased by PGI2 (2.6 ± 0.3 nM,
P < 0.05) and even more so by the combination of
DEA/NONOate + PGI2 (4.9 ± 0.6 nM, P < 0.05). Neither
PAM, aspirin nor PAM + aspirin altered the cAMP re-
sponse in collagen-stimulated platelets (Figure 3C). In
contrast, in TRAP-6-stimulated platelets, DEA/NONOate,
PGI2 and the combination did not elevate cAMP levels
in vehicle or aspirin groups, but did in the presence of
PAM (1.0 ± 0.1 nM to 2.3 ± 0.2 nM, P< 0.05) or PAM + aspi-
rin (1.4 ± 0.5 nM to 2.2 ± 0.4 nM, P < 0.05), PGI2 increased
cAMP levels and this response was further enhanced byBr J Clin Pharmacol / 81:4 / 625
Table 1A
In vitro effects of aspirin and PAM on platelet aggregation. PRP from healthy volunteers (n = 4) was treated with PAM (1.5 μM, 3 μM and 6 μM)
to represent 25%, 50% and 100% maximum concentration for total P2Y12 receptor inhibition, respectively. Tables show % ﬁnal aggregation in
response to ADP (20 μM), collagen (4 μg ml1) and TRAP-6 (25 μM) in the presence of vehicle (NaOH, 10 mM), NO (100 nM), PGI2 (1 nM) or
NO + PGI2 in the (A) absence and (B) presence of aspirin (30 μM).
% of maximum
concentration for total P2Y12
receptor inhibition Vehicle NO PGI2 NO + PGI2
ADP (20 μM) 0% 80 ± 6 75 ± 2 72 ± 5 23 ± 6 *†
25% 70 ± 5 49 ± 13 30 ± 7 * 12 ± 2 *
50% 45 ± 15 8 ± 3 * 4 ± 1 * 0 ± 0 *
100% 4 ± 1 0 ± 0 * 0 ± 0 * 0 ± 0 *
Collagen (4 μg ml1) 0% 79 ± 4 74 ± 4 74 ± 4 50 ± 10 *†
25% 74 ± 3 60 ± 10 58 ± 6 21 ± 10 *†
50% 71 ± 4 43 ± 14 * 36 ± 8 * 6 ± 2 *†
100% 56 ± 11 23 ± 9 * 22 ± 6 * 4 ± 1 *
TRAP-6 (25 μM) 0% 69 ± 2 70 ± 2 67 ± 2 63 ± 3
25% 67 ± 2 63 ± 3 61 ± 2 39 ± 10 *†
50% 65 ± 4 63 ± 0 55 ± 3 20 ± 6 *†
100% 59 ± 3 36 ± 6 * 35 ± 3 * 4 ± 2 *†
Table 1B
% of maximum
concentration for total P2Y12
receptor inhibition Vehicle NO PGI2 NO + PGI2
ADP (20 μM) 0% 73 ± 5 59 ± 5 52 ± 10 26 ± 13 *
aspirin +0% 51 ± 7 37 ± 9 * 38 ± 10 * 13 ± 9 *†
aspirin +25% 33 ± 11 16 ± 8 17 ± 7 5 ± 4 *
aspirin +50% 23 ± 8 6 ± 4 9 ± 4 1 ± 1
aspirin +100% 7 ± 1 0 ± 0 * 0 ± 0 * 0 ± 0 *
Collagen (4 μg mL1) 0% 71 ± 2 67 ± 5 68 ± 11 62 ± 5
aspirin +0% 50 ± 18 29 ± 20 36 ± 28 10 ± 10
aspirin +25% 26 ± 7 8 ± 4 * 11 ± 5 4 ± 2 *
aspirin +50% 24 ± 8 7 ± 4 * 7 ± 4 * 3 ± 1 *
aspirin +100% 15 ± 5 3 ± 2 5 ± 2 2 ± 1
TRAP-6 (25 μM) 0% 75 ± 4 72 ± 4 71 ± 4 67 ± 5
aspirin +0% 71 ± 4 65 ± 6 69 ± 3 50 ± 13
aspirin +25% 70 ± 4 61 ± 8 65 ± 5 36 ± 13 *†
aspirin +50% 67 ± 6 56 ± 9 62 ± 5 33 ± 15 *
aspirin +100% 56 ± 5 31 ± 12 46 ± 7 15 ± 8 *†
Signiﬁcance is shown as *P < 0.05 vs. vehicle, †P < 0.05 vs. PGI2.
M. V. Chan et al.addition of DEA/NONOate (PAM 3.4 ± 0.6 nM, PAM + aspi-
rin 3.5 ± 0.6 nM, P < 0.05, Figure 3D).
Phospho (Ser239)-VASP, a downstream marker of PKG
activation, remained unchanged inmost conditions studied
but was increased following TRAP-6 stimulation in the pres-
ence of PAM in all cases andmost so in the presence of PGI2
(28 ± 5 to 47 ± 15 units, P < 0.05) or DEA/NONOate + PGI2
(27 ± 4 to 46 ± 11 units, P < 0.05, Figure 3F).Discussion
Here we show in healthy individuals receiving standard
DAPT leading to consensus levels of platelet inhibition626 / 81:4 / Br J Clin Pharmacolthat ex vivo responses to the strong primary platelet
activators collagen and TRAP-6 are powerfully inﬂuenced
by the presence of NO and PGI2. The strong synergies
between P2Y12 inhibitors and the cAMP and cGMP sig-
nalling systems mean that the in vivo platelet reactivity
in patients receiving DAPT will be a function of the level
of P2Y12 receptor blockade and the levels of endothe-
lium-derived NO and PGI2. This provides an explanation
for different thrombotic outcomes in the presence of
similar levels of platelet blockade, i.e. individual patients
with different levels of endothelial function, or indeed
disease-driven endothelial dysfunction, would have dif-
ferent levels of in vivo platelet inhibition for the same
level of DAPT activity, as determined by ex vivo testing.
Table 2A
In vitro effects of aspirin and PAM on ATP release. PRP from healthy volunteers (n = 4) was treated with PAM (1.5 μM, 3 μM and 6 μM) to
represent 25%, 50% and 100% maximum concentration for total P2Y12 receptor inhibition, respectively. Tables show ATP release (nM) in
response to collagen (4 μg ml1) and TRAP-6 (25 μM) in the presence of vehicle (NaOH, 10 mM), NO (100 nM), PGI2 (1 nM) or NO + PGI2 in
the (A) absence and (B) presence of aspirin (30 μM).
% of maximum
concentration for total P2Y12
receptor inhibition Vehicle NO PGI2 NO + PGI2
Collagen (4 μg ml
1
) 0% 10.8 ± 3.3 9.8 ± 2.5 7.1 ± 2.4 6.0 ± 1.3
25% 11.0 ± 3.0 8.8 ± 2.7 7.2 ± 1.6 4.1 ± 1.7
50% 10.1 ± 2.9 6.4 ± 2.0 8.3 ± 2.9 4.0 ± 1.8
100% 8.2 ± 2.1 5.2 ± 1.7 6.5 ± 2.2 2.3 ± 0.5 *
TRAP-6 (25 μM) 0% 13.0 ± 1.0 13.0 ± 2.1 11.5 ± 1.5 9.7 ± 1.5
25% 10.0 ± 2.0 11.7 ± 2.2 12.5 ± 2.5 7.0 ± 2.0
50% 11.7 ± 2.6 9.3 ± 3.5 13.5 ± 0.5 10.3 ± 1.9
100% 11.7 ± 3.7 6.0 ± 2.0 10.7 ± 2.9 3.0 ± 1.5
Table 2B
% of maximum
concentration for total P2Y12
receptor inhibition Vehicle NO PGI2 NO + PGI2
Collagen (4 μg ml1) 0% 7.7 ± 1.1 6.6 ± 0.8 7.6 ± 0.6 8.0 ± 0.5
aspirin +0% 3.4 ± 0.5 3.5 ± 0.2 3.7 ± 0.4 3.3 ± 0.2
aspirin +25% 3.6 ± 0.2 2.9 ± 0.4 3.0 ± 0.3 1.9 ± 0.3 *
aspirin +50% 3.4 ± 0.5 2.1 ± 0.3 * 2.3 ± 0.3 2.1 ± 0.3 *
aspirin +100% 2.9 ± 1.0 1.9 ± 0.5 2.3 ± 0.8 1.8 ± 0.2
Collagen (10 μg ml1) 0% 8.8 ± 1.1 8.3 ± 1.1 9.1 ± 0.9 8.4 ± 2.5
aspirin +0% 5.9 ± 0.9 4.6 ± 0.7 4.8 ± 0.5 3.6 ± 0.5 *
aspirin +25% 5.6 ± 0.6 4.2 ± 0.2 * 4.5 ± 0.3 3.7 ± 0.4 *
aspirin +50% 5.2 ± 0.3 4.1 ± 0.1 4.3 ± 0.5 3.5 ± 0.6 *
aspirin +100% 3.8 ± 0.2 2.4 ± 0.2 3.4 ± 0.4 3.0 ± 0.6
TRAP-6 (25 μM) 0% 11.4 ± 3.0 13.0 ± 1.6 11.7 ± 2.8 10.7 ± 2.9
aspirin +0% 12.4 ± 0.3 11.6 ± 1.0 10.2 ± 0.7 7.3 ± 1.1 *†
aspirin +25% 11.4 ± 1.4 9.1 ± 2.2 10.6 ± 1.3 6.8 ± 1.1
aspirin +50% 7.9 ± 0.9 7.5 ± 1.2 8.6 ± 1.6 5.3 ± 1.2
aspirin +100% 10.7 ± 2.1 8.7 ± 1.8 9.5 ± 1.6 5.0 ± 1.1 *
Signiﬁcance is shown as *P < 0.05 vs. vehicle, †P < 0.05 vs. PGI2.
NO and PGI2 synergize with P2Y12 receptor blockadeDAPT, aspirin plus a P2Y12 receptor blocker, is the
preventative therapy provided to patients at particular risk
of coronary thrombosis, notably for the ﬁrst 12 months
following coronary stent implantation or an acute coronary
syndrome [20, 21]. Despite this therapeutic approach coro-
nary thrombosis still occurs, and there have been great
efforts made to ﬁnd ex vivo tests that could predict for clin-
ical outcomes [22, 23]. Deductive reasoning leads to the
conclusion that less effective platelet blockade would
leave individuals at increased risk of thrombosis and so
multiple efforts have been made to link levels of platelet
reactivity in ex vivo tests to clinical outcomes. Despite the
attractive logic of this approach, tailoring anti-platelet ther-
apy to ex vivo platelet responses has failed to provide any
improvement in clinical outcomes as noted in large scale
studies such as ADRIE [24] and several large scale
prospective, randomized clinical trials, such as GRAVITAS
[7], ARCTIC [8], TRIGGER-PCI [9] and TRILOGY [10].In patients receiving clopidogrel, there are well-
characterized metabolic differences that can produce
suboptimal levels of its active metabolite and conse-
quently result in suboptimal levels of P2Y12 receptor
blockade [25]. There are also some reports of variability
in the effects of prasgurel and ticagrelor, although to a
much lesser extent than for clopidogrel [26]. Biochemi-
cal resistance to the effects of aspirin are also particu-
larly rare [27]. Allowing for differences dependent
upon adherence to therapy, individuals on DAPT may
in fact present a rather more homogenous level of
platelet inhibition than can be associated to different
clinical outcomes. Having recently reported that block-
ade of P2Y12 receptors greatly increases the inhibitory
effects of NO, and knowing that not only was there a
similar interaction with the inhibitory effects of PGI2
but that NO and PGI2 powerfully synergize to inhibit
platelets, we reasoned that differences in the levels ofBr J Clin Pharmacol / 81:4 / 627
Figure 2
Synergism between NO, PGI2 and PAM. IC50 isobolograms were generated by analyzing combinations of NO and PGI2 required to produce a 50% inhi-
bition of platelet aggregation stimulated by collagen (30 μg ml1) in the (A) absence and (B) presence of PAM (6 μM) and by TRAP-6 (25 μM) in the (C)
absence and (D) presence of PAM. The linear relationship is predicted by the arithmetic sum of the effect of either NO or PGI2 alone, as described in the
methods, and the experimental line curving towards the axes indicates a strong, synergistic relationship. n = 4 for each point
M. V. Chan et al.NO and PGI2 in the presence of the same levels of
P2Y12 receptor blockade would produce different levels
of platelet inhibition. By testing this hypothesis in indi-
viduals receiving standard DAPT we show here that
strong and synergistic interactions between P2Y12 re-
ceptor blockade and endothelium-derived mediators
produce profound inhibitory effects upon platelets.
We ﬁrstly established that the drug regime given in
our studies elicited satisfactory reduction in baseline
reactivity, therefore establishing effectiveness of P2Y12
and/or COX inhibition in accordance with suggested
analytical cutoffs [28]. These reductions were against
high pre-treatment levels of platelet reactivity (>70%
response to 5 μM ADP) [29]. In these studies, and
others presented here, we took care to include the
standard measures of platelet function as determined
in consensus statements [28, 30]. Then to make data
readily accessible we have presented results in the
form of heat maps that move from red to green, indi-
cating movement from full platelet activation to no
platelet activation.
It is well known that NO and PGI2 synergize to inhibit
platelets [12] and it has been demonstrated by ourselves
and others that P2Y12 antagonists potentiate the inhibi-
tory actions of both PGI2, dependent upon cAMP [17],
and NO, dependent upon cGMP generation [18]. Here,
we have shown that this synergy, in the presence of NO
and PGI2 is mostly cAMP dependent. Therefore628 / 81:4 / Br J Clin Pharmacolphosphodiesterase 3 (PDE3) inhibitors, such as cilostazol,
may have an enhanced effect compared with PDE5
inhibitors, such as sildenaﬁl. Though not widely
commented upon, the body contains many more endo-
thelial cells than platelets, in the order of 50 times more,
and the two populations constantly interact. In the circu-
lation DAPT exerts its effects upon platelets in the pres-
ence of endothelium-derived mediators while these are
absent in ex vivo testing. In the studies presented here
we found that the interactions of NO, PGI2 and P2Y12 re-
ceptor blockade in inhibiting platelets were markedly
synergistic as noted by isobolographic analysis and mea-
sures of aggregation, ATP release, activation of GP IIb/IIIa
receptors and P-selectin expression. In volunteers taking
DAPT we noted inhibition of responses to ADP and AA
that were in keeping with consensus statements of
effective DAPT, i.e. in our study the drugs were work-
ing to an effective level of clinical efﬁcacy. Despite this
level of effective inhibition, high concentrations of the
strong primary platelet activators, TRAP-6 or collagen,
still caused notable platelet activation. Addition of
low concentrations of NO and PGI2, to model the
environment within the blood vessel, had little effect
on their own but led to almost complete inhibition in
platelets from individuals treated with DAPT. Similarly,
while NO, PGI2 or DAPT alone had relatively little effect
upon platelet granule release, determined as ATP
release, when combined they caused more than 50%
Figure 3
In vitro effects of aspirin and PAM on cyclic nucleotide levels. PRP from healthy volunteers (n = 4) was treated with aspirin (30 μM), PAM (6 μM) or both
followed by addition of vehicle (NaOH, 10 mM), NO (100 nM), PGI2 (1 nM) or NO + PGI2. cGMP levels were then measured following stimulation by (A)
collagen (4 μg ml1) and (B) TRAP-6 (25 μM) as were cAMP levels following (C) collagen and (D) TRAP-6. Phospho (Ser239)-VASP levels in (E) collagen
and (F) TRAP-6-stimulated PRP were determined by ﬂow cytometry as a composite of cGMP and cAMP responses. Signiﬁcance is shown as * P < 0.05
vs. non-treated and † P < 0.05 PGI2 with corresponding PAM or aspirin + PAM. ( ) vehicle, ( ) aspirin, ( ) pam, ( ) aspirin + PAM
NO and PGI2 synergize with P2Y12 receptor blockadeinhibition. These results indicate that even in the pres-
ence of effective DAPT, i.e. within consensus guide-
lines, the presence of NO and PGI2 lead to very
much higher levels of platelet inhibition.Next using an in vitro approach we modelled events
in the presence of suboptimal levels of P2Y12 receptor
blockade by using concentrations of PAM that were
50% and 25% of the effective concentration. Under theseBr J Clin Pharmacol / 81:4 / 629
M. V. Chan et al.conditions we noted that relative to the consensus levels
of DAPT we did not achieve signiﬁcant reduction in plate-
let aggregation. Notably, however, in the presence of NO
and PGI2 effective levels of inhibition were achieved,
even when platelets were exposed to only 25% of the ef-
fective concentration of PAM. As we express in heat
maps, there is a clear interaction between DAPT and
the endothelial mediators that move platelets from reac-
tive (‘red’) to unreactive (‘green’). Interestingly, these
comparisons indicate that 25% of the effective concen-
tration of PAM plus NO and PGI2 produces a stronger in-
hibition in LTA, the ‘gold standard test’, than 100% of the
effective concentration of PAM in the absence of NO and
PGI2 (i.e. the normal conditions for testing ex vivo platelet
responsiveness). This suggests that in individuals in
whom suboptimal P2Y12 inhibition is achieved, such as
poor clopidogrel metabolizers, anti-platelet efﬁcacy
may be particularly sensitive to any changes in endothe-
lial function. Our in vitro data also demonstrate that the
triple synergy between P2Y12 blockade, NO and PGI2
can be explained by changes in cAMP signalling, whichFigure 4
Summary of the interaction between the endothelium and P2Y12 antagonism. In
in part by the action of endothelium-derived mediators, NO and PGI2. At areas
adherence and activation. This effect is partly driven by stimulation of P2Y12
P2Y12 receptors inhibits the effects of cAMP and cGMP within platelets, mak
P2Y12 receptors are blocked, cAMP and cGMP pathways are not inhibited by AD
effectiveness of P2Y12 receptor blockade and DAPT in vivo is therefore strongly
630 / 81:4 / Br J Clin Pharmacolis consistent with known interactions between NO and
PGI2 [31] and PGI2 and P2Y12 [17].
We show that following standard DAPT the level of
platelet reactivity is a function of the level of P2Y12 recep-
tor blockade and the levels of NO and PGI2. While we
added NO and PGI2 exogenously they are surrogates for
the effects of endogenous NO and PGI2 and other eleva-
tors of platelet cyclic nucleotides such as adenosine. We
propose that, since in vivo platelet function is a product
of both internal platelet responsive signalling reactivity
and the external inﬂuence of the endothelium, an assess-
ment of endothelial mediator production could be com-
bined with results from ex vivo platelet testing to predict
thrombotic outcomes better in individual patients. Fur-
thermore, with the emergence of this complex and very
powerful synergy between PGI2, NO and P2Y12
inhibitors (Figure 4), we should perhaps consider
optimizing the availability and activity of endothelium-
derived mediators (such as PDE inhibitors), or providing
mimetic drugs, rather than adding in further anti-platelet
therapies. These ﬁndings could, eventually, be applied inthe healthy intact circulation platelets are kept in a non-activated state
of endothelial damage platelets become activated leading to platelet
receptors following from platelet release of ADP. This stimulation of
ing platelets more excitable, and amplifying platelet activation. When
P and the inhibitory effects of NO and PGI2 are sustained. The inhibitory
dependent upon the production of NO and PGI2 within the circulation
NO and PGI2 synergize with P2Y12 receptor blockadea personalized medicine framework where the endothe-
lial mediator production of individuals is assessed and
appropriate add-on therapy applied. In a more general-
ized approach these additional therapies could also be
supplied to patient groups with known endothelial
dysfunction, such as diabetics. This approach could
provide increased anti-platelet efﬁcacy while avoiding
the increased risk of bleeding events associated with
the approach of triple anti-platelet therapy.Competing Interests
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Figure S1
Standard platelet aggregation tests. Standard light
transmission aggregometry responses to AA (1 mM),
ADP (5 μM), collagen (0.4 μg ml1) and U46619 (10 μM)
in healthy volunteers before and following treatment
with (A) aspirin (75 mg), (B) prasugrel (10 mg) or (C) DAPT
(aspirin, 75 mg, plus prasugrel, 10 mg) for 7 days. n = 8 for
all. Signiﬁcance is shown as * P < 0.05 vs. non-treated
Figure S2
The effect of DAPT on platelet aggregation and ATP re-
lease. Representative light transmission aggregometry
traces of PRP before and after DAPT (aspirin, 75 mg, plus
prasugrel, 10 mg) treatment in the presence of vehicle
(NaOH, 10 mM), DEA/NONOate (100 nM), PGI2 (1 nM) or
DEA/NONOate + PGI2 following stimulation with (A) col-
lagen (4 μg ml1) or (B) TRAP-6 amide (25 μM). (C) Repre-
sentative lumi-aggregometry traces in the same
conditions after TRAP-6 amide (25 μM) stimulation, where
ATP release is measured as an increase in voltage
Figure S3
The effect of aspirin and prasugrel on platelet aggrega-
tion. Healthy volunteers (n = 8) were treated with aspirin
(75 mg) or prasugrel (10 mg) for 7 days. Aggregometry
was conducted in the presence of vehicle (NaOH,
NO and PGI2 synergize with P2Y12 receptor blockade10 mM), DEA/NONOate (100 nM), PGI2 (1 nM) or DEA/
NONOate + PGI2 before and after aspirin, using as ago-
nists (A) collagen (4 μg ml1) or (B) TRAP-6 amide
(25 μM), and before and after prasugrel, also using (C) col-
lagen (4 μg ml1) or (D) TRAP-6 amide (25 μM). Data are
presented as ﬁnal aggregation (%, mean ± SEM). Sum-
mary heatmaps after stimulation with (E) collagen
(4 μg ml1) or (F) TRAP-6 amide (25 μM) indicate maximum
aggregation with red andminimum aggregation with green,
before treatment and after aspirin (75mg), prasugrel (10mg)
or DAPT for 7 days. n = 8 for all. Signiﬁcance is shown as
* P < 0.05 vs. non-treated, † P < 0.05 vs. NaOH drug-treated
‡ P < 0.05 vs. PGI2 drug-treated
Figure S4
The effect of aspirin and prasugrel on platelet ATP release.
Healthy volunteers (n = 8) were treated with aspirin
(75 mg) or prasugrel (10 mg) for 7 days. Lumi-
aggregometry was conducted in the presence of vehicle
(NaOH, 10 mM), DEA/NONOate (100 nM), PGI2 (1 nM), or
DEA/NONOate + PGI2 before and after (A) aspirin or (B)
prasugrel, using collagen (4 μg ml1) as an agonist. Data
are presented as maximum ATP release (%, mean ± SEM).
(C) A summary heatmap after stimulation with collagen
(4 μg ml1) indicates maximum ATP release with red and
minimum ATP release with green before treatment and af-
ter aspirin (75 mg), prasugrel (10 mg) or DAPT for 7 days.
n = 8 for all. Signiﬁcance is shown as * P < 0.05 vs. non-treated, † P < 0.05 vs. NaOH drug-treated ‡ P < 0.05 vs.
PGI2 drug-treated
Figure S5
Representative control data for ﬂow cytometry experi-
ments. GPIIb/IIIa activation by PAC-1 binding in the
(A) absence and (B) presence of DAPT, P-selectin ex-
pression in the (C) absence and (D) presence of DAPT
and VASP phosphorylation (Ser239) in the (E) absence
and (F) presence of DAPT was measured by ﬂow cy-
tometry in PRP stimulated with TRAP-6 (25 μM) in the
presence of vehicle (NaOH, 10 mM), DEA/NONOate
(100 nM), PGI2 (1 nM) or DEA/NONOate + PGI2. Histo-
grams are representative of n = 3
Figure S6
The effect of aspirin, prasugrel and DAPT on P-selectin
and glycoprotein IIb/IIIa. Healthy volunteers (n = 8)
were treated with aspirin (75 mg), prasugrel (10 mg),
or DAPT for 7 days. Heatmaps in response to TRAP-6
amide (25 μM)-stimulated PRP before and after DAPT
treatment in the presence of vehicle (NaOH, 10 mM),
DEA/NONOate (100 nM), PGI2 (1 nM) or DEA/
NONOate + PGI2 were generated for (A) CD62P
(P-selectin) and (B) PAC-1 (GPIIb/IIIa binding). Red rep-
resents maximum expression and green shows mini-
mum expression with each cell representing data
from three groups of eight subjectsBr J Clin Pharmacol / 81:4 / 633
